SCHEMBL5533958

SCHEMBL5533958

CC(=O)Cc1cc(C)ccc1Nc1c(F)cccc1Cl

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.82
PTGS1 P23219 5/20 0.82
ABCB11 O95342 2/20 0.82
NR1I3 Q14994 2/20 0.82
PPARG P37231 1/20 0.82
CAMK2A Q9UQM7 2/20 0.50
TTR P02766 2/20 0.44
AKR1B10 O60218 1/20 0.44
UGT1A9 O60656 1/20 0.44
TRPA1 O75762 1/20 0.44
MT-CO2 P00403 1/20 0.44
ALB P02768 1/20 0.44
CXCL8 P10145 1/20 0.44
UGT1A6 P19224 1/20 0.44
UGT1A1 P22309 1/20 0.44
CXCR1 P25024 1/20 0.44
ADRA1A P35348 1/20 0.44
AGTR2 P50052 1/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
NR1H4 Q96RI1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lumiracoxib SCHEMBL29475008 0.90 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL4479 0.90 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL29377334 0.90 PTGS2 (1.00) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL27680523 0.89 PTGS2 (0.98) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL5534966 0.88 PTGS2 (0.79) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL17208147 0.88 PTGS2 (0.79) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL16746714 0.88 PTGS2 (0.65) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL576935 0.87 PTGS2 (0.77) PTGS2PTGS1ABCB11NR1I3PPARG
SCHEMBL3885542 0.85 PTGS2 (0.73) PTGS2PTGS1ABCB11NR1I3PPARG
Lumiracoxib SCHEMBL6063194 0.84 PTGS2 (0.87) PTGS2PTGS1ABCB11NR1I3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4238571-A1 APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS OnQuality Pharmaceuticals China Ltd. (CN) 2023-09-06 EP disclosed
US-20150306232-A1 HYDROGELATORS COMPRISING D-AMINO ACIDS BRANDEIS UNIVERSITY 2015-10-29 US disclosed
WO-2014091467-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATION KANDULA MAHESH (IN) 2014-06-19 WO disclosed
WO-2014083476-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIPID DISORDERS KANDULA MAHESH (IN) 2014-06-05 WO disclosed
WO-2014068463-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND METABOLIC DISORDERS KANDULA MAHESH (IN) 2014-05-08 WO disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S.A. (BR) 2012-05-10 US disclosed
EP-2418200-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES EMS S. A. (BR) 2012-02-15 EP disclosed
US-7645747-B2 Improved pharmacokinetic properties, oral bioavailability; side effect reduction GILEAD SCIENCES, INC. (US) 2010-01-12 US disclosed
US-20090247488-A1 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS CANNIZZARO CARINA 2009-10-01 US disclosed
US-7432261-B2 Anti-inflammatory phosphonate compounds GILEAD SCIENCES, INC. (US) 2008-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247488-A1 ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS PHOSPHO1, TNF, PTGES PTGS2 13/4885PTGS1 6/4885ABCB11 2592/4885
US-20150306232-A1 HYDROGELATORS COMPRISING D-AMINO ACIDS DNPEP, S100A10, S100A11 PTGS2 622/4885PTGS1 239/4885ABCB11 3103/4885
US-20120115817-A1 PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES TNF, PER2, CRY1 PTGS2 12/4885PTGS1 8/4885ABCB11 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.